Meta AnalysisID 4351
抗性淀粉对血液透析患者尿毒症毒素的疗效：一项系统评价与Meta分析
CRD42020160332
Whether could hemoialysis chronic kidney disease (CKD) patients benefit from resistant starch? How do the uremic toxins of CKD patients change after taking resistant starch comparing with placebo? What is the adverse eve
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 4351
- Evidence Id
- 12909
- Core Evidence Id
- 12909
- Source Meta Analysis Id
- 4318
- Herb2 Meta Analysis Id
- HBMA004318
- Crd Id
- CRD42020160332
- Title
- Efficacy of resistant starch on uremic toxins in hemodialysis patients: a systematic review and meta-analysis
- Review Question
- Whether could hemoialysis chronic kidney disease (CKD) patients benefit from resistant starch? How do the uremic toxins of CKD patients change after taking resistant starch comparing with placebo? What is the adverse events of this new drug?
- Study Type Included
- RCTs only.
- Condition Being Studied
- Chronic kidney disease. resistant starch effectiveness on uremic toxins in hemodialysis adults.
- Participant
- Inclusion: RCTs in which the resistant starch were administered for at least 4 weeks to adult hemodialysis CKD patients were included. Exclusion: Animal studies, in vitro experiments, and non-RCT clinical trials, as well as publications lacking sufficient data, such as narrative review, case reports/series and conference abstracts, were excluded. Patients with active infectious conditions, pregnancy, autoimmune diseases, cancers or enrolled in another clinical trails within 6 months prior to enrolment. Adolescents are also excluded.
- Animal
- Human Disease Modelled
- Intervention
- Resistant starch were administered for at least 4 weeks.
- Comparator Control
- Placebo only.
- Main Outcome
- P-cresyl sulfate, indoxyl sulfate, interleukin 6, blood urea nitrogen Measures of effect The primary measured outcomes were changes of p-cresyl sulfate, indoxyl sulfate, interleukin 6, blood urea nitrogen from baseline to the last available follow-up by clinical laboratory examination.
- Outcome Measure
- Additional Outcome
- The additional outcomes were severe adverse events and adverse events Measures of effect Adverse events were recorded from the baseline to the last available follow-up and judged by clinical diagnosis.
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Humans; Indican; Renal Dialysis; Resistant Starch; Uremia; Uremic Toxins
- Contact
- Linpei Jia [email protected]
- Organisational Affiliation
- Xuanwu Hospital of Capital Medical University https://www.xwhosp.com.cn/
- Funding Source
- Wu Jieping Medical Foundation Clinical Research Funding (No. 320.6750.16050)
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2019-11-28
- Registration Date
- 2020-04-28
- Anticipated Start Date
- 2019-12-08
- Anticipated Completion Date
- 2020-04-30
- Title Cn
- 抗性淀粉对血液透析患者尿毒症毒素的疗效：一项系统评价与Meta分析
- Title En
- Efficacy of resistant starch on uremic toxins in hemodialysis patients: a systematic review and meta-analysis
- Bilingual Status
- complete